STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Autolus Therapeutics plc SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Wellington Management filed an amended Schedule 13G reporting its position in Autolus Therapeutics plc (AUTL) common stock. The filing lists three related Wellington entities organized in MASSACHUSETTS and DELAWARE that collectively report 0.0% beneficial ownership of the class and 0 shares of sole voting or dispositive power. The securities are owned of record by clients of Wellington investment advisers and are held in the ordinary course of business, with no client reported as having more than 5% of the class. The cover lists the issuer address in London and the event date 09/30/2025; the filing is signed on 10/07/2025 by a Wellington regulatory analyst.

Positive
  • Clear disclosure of entity structure and reporting chain among Wellington affiliates
  • Certifies ordinary-course holdings and explicitly states no client holds more than 5% of the class
  • Timely amendment with event date 09/30/2025 and signature dated 10/07/2025
Negative
  • No beneficial ownership reported (0.0%), indicating no economic or voting exposure from these filers

Insights

TL;DR: Wellington reports no beneficial stake in AUTL as of 09/30/2025.

The filing identifies three Wellington-related entities and multiple Wellington investment advisers as record owners for client accounts, but shows an aggregate beneficial ownership of 0.0% and zero shares of sole or shared voting and dispositive power. This indicates Wellington does not hold a reportable economic or voting position in the common stock class.

The position is described as held in the ordinary course of business with no client exceeding 5% of the class. Investors looking for changes in ownership should note the 09/30/2025 event date and the 10/07/2025 signature; subsequent filings would disclose any new positions.

TL;DR: This Schedule 13G/A confirms non-activist, non-controlling record holdings by Wellington-affiliated advisers.

The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing control. The filing lists parent/subsidiary relationships among Wellington entities, clarifying reporting chain and the advisers exercising record ownership for clients.

Key governance watchers should note there is no group formation or >5% ownership disclosed, so there are no reported voting blocs or control-related disclosures tied to these Wellington entities at the stated date.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Wellington Management Group LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:10/07/2025
Wellington Group Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:10/07/2025
Wellington Investment Advisors Holdings LLP
Signature:Taisia Lowe
Name/Title:Regulatory Analyst
Date:10/07/2025

FAQ

What does the Schedule 13G/A filed by Wellington mean for AUTL (AUTL) ownership?

The filing shows Wellington-related entities report an aggregate beneficial ownership of 0.0% in AUTL common stock, meaning they do not hold a reportable economic or voting stake in the class.

Who filed the Schedule 13G/A for Autolus Therapeutics (AUTL)?

The filing was made by Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP, with a principal address c/o Wellington Management Company LLP, 280 Congress Street, Boston, MA.

What date does the filing cover and when was it signed?

The event date requiring the filing is 09/30/2025 and the signature date on the amendment is 10/07/2025.

Does Wellington claim any intent to influence control of Autolus Therapeutics (AUTL)?

No; the certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.

Are any Wellington clients reported as owning more than 5% of AUTL?

No; the filing states no client is known to have the right or power with respect to more than 5% of the class.
AUTOLUS THERAPEUTICS PLC

NASDAQ:AUTL

AUTL Rankings

AUTL Latest News

AUTL Latest SEC Filings

AUTL Stock Data

327.36M
213.38M
18.09%
84.09%
3.8%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United Kingdom
LONDON